Vivo Capital’s SAB Biotherapeutics SABS Stock Holding History

Vivo Capital’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$43.7M	Hold	11,420,000	–	–	3.64%	8
2025 Q4	$42.7M	Hold	11,420,000	–	–	2.76%	11
2025 Q3	$23M	Buy	+11,420,000	New	+$25.8M	1.85%	18

Other funds holding SABS

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SSC

Spruce Street Capital New York $416M AUM

Vivo Capital's SABS Position: Q1 2026 in Review

Vivo Capital held its SAB Biotherapeutics (SABS) position steady in Q1 2026 at 11,420,000 shares worth $43.7M. The position accounts for 3.64% of the portfolio, ranked #8.

Vivo Capital first reported a position in SABS in Q3 2025 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

Vivo Capital held 11,420,000 shares of SAB Biotherapeutics worth $43.7M as of Q1 2026.
Vivo Capital left its SAB Biotherapeutics share count unchanged in Q1 2026.
SAB Biotherapeutics made up 3.64% of Vivo Capital's portfolio in Q1 2026, its #8 holding.
Vivo Capital first reported a position in SAB Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.